vs
Side-by-side financial comparison of CuriosityStream Inc. (CURI) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $19.2M, roughly 1.1× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -20.4%, a 0.7% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs 6.9%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-2.0M). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs 2.9%).
Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CURI vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $20.4M |
| Net Profit | $-3.8M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | -17.6% | -18.0% |
| Net Margin | -19.7% | -20.4% |
| Revenue YoY | 35.8% | 6.9% |
| Net Profit YoY | -34.6% | 64.9% |
| EPS (diluted) | $-0.07 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $20.4M | ||
| Q3 25 | $18.4M | $19.9M | ||
| Q2 25 | $19.0M | $19.6M | ||
| Q1 25 | $15.1M | $17.5M | ||
| Q4 24 | $14.1M | $19.1M | ||
| Q3 24 | $12.6M | $20.2M | ||
| Q2 24 | $12.4M | $21.4M | ||
| Q1 24 | $12.0M | $19.3M |
| Q4 25 | $-3.8M | $-4.2M | ||
| Q3 25 | $-3.7M | $-8.2M | ||
| Q2 25 | $784.0K | $-11.9M | ||
| Q1 25 | $319.0K | $-14.2M | ||
| Q4 24 | $-2.8M | $-11.8M | ||
| Q3 24 | $-3.1M | $-11.1M | ||
| Q2 24 | $-2.0M | $-12.3M | ||
| Q1 24 | $-5.0M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | -17.6% | -18.0% | ||
| Q3 25 | -24.5% | -39.7% | ||
| Q2 25 | 2.5% | -59.6% | ||
| Q1 25 | 0.5% | -79.2% | ||
| Q4 24 | -27.4% | -62.5% | ||
| Q3 24 | -25.8% | -55.7% | ||
| Q2 24 | -20.6% | -59.2% | ||
| Q1 24 | -30.4% | -76.4% |
| Q4 25 | -19.7% | -20.4% | ||
| Q3 25 | -20.4% | -41.0% | ||
| Q2 25 | 4.1% | -61.0% | ||
| Q1 25 | 2.1% | -80.8% | ||
| Q4 24 | -19.9% | -62.1% | ||
| Q3 24 | -24.3% | -54.9% | ||
| Q2 24 | -16.4% | -57.7% | ||
| Q1 24 | -42.0% | -84.4% |
| Q4 25 | $-0.07 | $-0.07 | ||
| Q3 25 | $-0.06 | $-0.16 | ||
| Q2 25 | $0.01 | $-0.23 | ||
| Q1 25 | $0.01 | $-0.28 | ||
| Q4 24 | $-0.05 | $-0.23 | ||
| Q3 24 | $-0.06 | $-0.22 | ||
| Q2 24 | $-0.04 | $-0.25 | ||
| Q1 24 | $-0.09 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.3M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $41.5M | $63.9M |
| Total Assets | $75.7M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.3M | $92.0M | ||
| Q3 25 | $27.8M | $92.4M | ||
| Q2 25 | $28.1M | $101.5M | ||
| Q1 25 | $33.4M | $108.8M | ||
| Q4 24 | $32.1M | $120.4M | ||
| Q3 24 | $33.2M | $118.6M | ||
| Q2 24 | $39.5M | $118.2M | ||
| Q1 24 | $38.8M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $41.5M | $63.9M | ||
| Q3 25 | $47.2M | $64.3M | ||
| Q2 25 | $49.8M | $70.0M | ||
| Q1 25 | $58.1M | $77.6M | ||
| Q4 24 | $57.8M | $87.5M | ||
| Q3 24 | $62.2M | $95.0M | ||
| Q2 24 | $64.8M | $101.6M | ||
| Q1 24 | $67.0M | $109.2M |
| Q4 25 | $75.7M | $115.3M | ||
| Q3 25 | $74.7M | $116.3M | ||
| Q2 25 | $78.7M | $122.0M | ||
| Q1 25 | $85.3M | $129.7M | ||
| Q4 24 | $86.2M | $142.8M | ||
| Q3 24 | $87.6M | $143.6M | ||
| Q2 24 | $90.9M | $149.7M | ||
| Q1 24 | $94.6M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-1.8M |
| Free Cash FlowOCF − Capex | $3.9M | $-2.0M |
| FCF MarginFCF / Revenue | 20.5% | -9.7% |
| Capex IntensityCapex / Revenue | 0.1% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $-1.8M | ||
| Q3 25 | $4.4M | $-8.7M | ||
| Q2 25 | $2.8M | $-7.5M | ||
| Q1 25 | $1.9M | $-11.6M | ||
| Q4 24 | $3.0M | $-3.5M | ||
| Q3 24 | $2.3M | $362.0K | ||
| Q2 24 | $2.2M | $-9.5M | ||
| Q1 24 | $666.0K | $-9.8M |
| Q4 25 | $3.9M | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | 20.5% | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | 0.1% | 0.8% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.5% | 0.0% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.0% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 6.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURI
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
